On Friday, Abbott Laboratories (NYSE: ABT) was 0.43% up from the session before settling in for the closing price of $117.26. A 52-week range for ABT has been $99.71 – $121.64.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 6.10%. When this article was written, the company’s average yearly earnings per share was at 5.29%. With a float of $1.72 billion, this company’s outstanding shares have now reached $1.73 billion.
Let’s determine the extent of company efficiency that accounts for 114000 employees. In terms of profitability, gross margin is 54.7%, operating margin of 16.73%, and the pretax margin is 16.44%.
Abbott Laboratories (ABT) Insider Activity
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Abbott Laboratories stocks. The insider ownership of Abbott Laboratories is 0.66%, while institutional ownership is 76.67%. The most recent insider transaction that took place on Nov 04 ’24, was worth 1,800,000. Before that another transaction happened on Oct 21 ’24, when Company’s EXECUTIVE VICE PRESIDENT sold 157,421 for $117.04, making the entire transaction worth $18,424,298. This insider now owns 184,806 shares in total.
Abbott Laboratories (ABT) Earnings and Forecasts
Going through the last 3-months fiscal report unveiled on the 9/30/2024, it has been observed that the corporation posted 1.19 earnings per share (EPS) during the time that was better than consensus figure (set at 1.19) by 0. Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 5.29% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 8.15% during the next five years compared to 19.65% growth over the previous five years of trading.
Abbott Laboratories (NYSE: ABT) Trading Performance Indicators
You can see what Abbott Laboratories (ABT) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 1.14. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.98. Likewise, its price to free cash flow for the trailing twelve months is 31.63.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 3.29, a number that is poised to hit 1.34 in the next quarter and is forecasted to reach 5.16 in one year’s time.
Technical Analysis of Abbott Laboratories (ABT)
Looking closely at Abbott Laboratories (NYSE: ABT), its last 5-days average volume was 5.43 million, which is a drop from its year-to-date volume of 5.7 million. As of the previous 9 days, the stock’s Stochastic %D was 72.21%. Additionally, its Average True Range was 2.10.
During the past 100 days, Abbott Laboratories’s (ABT) raw stochastic average was set at 84.78%, which indicates a significant increase from 50.68% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 12.82% in the past 14 days, which was lower than the 20.05% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $115.58, while its 200-day Moving Average is $110.83. However, in the short run, Abbott Laboratories’s stock first resistance to watch stands at $118.38. Second resistance stands at $119.00. The third major resistance level sits at $120.00. If the price goes on to break the first support level at $116.76, it is likely to go to the next support level at $115.76. Should the price break the second support level, the third support level stands at $115.14.
Abbott Laboratories (NYSE: ABT) Key Stats
There are 1,734,455K outstanding shares of the company, which has a market capitalization of 205.12 billion. As of now, sales total 40,109 M while income totals 5,723 M. Its latest quarter income was 10,635 M while its last quarter net income were 1,646 M.
